Simcere to Commercialize Lynk's JAK1 Inhibitor in China
publication date: Mar 18, 2022
Simcere, a Nanjing biopharma, acquired China commercialization rights to a selective JAK1 inhibitor from Lynk Pharma of Hangzhou. Simcere will market LNK01001 to patients with rheumatoid arthritis and ankylosing spondylitis. Lynk will continue to be responsible for clinical development of the candidate, while Simcere will make unspecified payments to acquire the rights. Earlier this year, Lynk started a double-blind, placebo-controlled China Phase II trial of LNK01001 for ankylosing spondylitis. In head-to-head clinical studies, JAK1 inhibitors have shown advantages over existing rheumatoid arthritis treatments, according to Lynk. More details....
Stock Symbol: (HK: 2096)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.